Chemotherapy can absolutely cause a cough, and it does so through several different pathways. The lungs are the organ most commonly affected by chemotherapy-related complications, whether from direct drug toxicity, infections that take hold when the immune system is suppressed, or inflammation triggered by the body’s own immune response to treatment. The tricky part is figuring out which of these causes is behind your cough, because the answer changes what you should do about it.
How Chemotherapy Damages the Lungs Directly
Certain chemotherapy drugs are directly toxic to lung tissue. When these drugs circulate through the bloodstream, they can injure the delicate lining of the air sacs and the tissue between them, triggering inflammation that shows up as a persistent dry cough, shortness of breath, or both. In a case series evaluating patients who developed persistent respiratory symptoms after chemotherapy, dry cough and difficulty breathing were among the most common complaints, and high-resolution CT scans typically revealed ground-glass opacities in the lungs. The drugs most frequently responsible were paclitaxel, fluorouracil, gemcitabine, and tyrosine kinase inhibitors.1PubMed Central. Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Center
The patterns of damage vary. Some drugs cause a diffuse inflammatory reaction across the lung tissue, while others trigger more localized injury. Radiological patterns linked to drug toxicity include interstitial and airway infiltrates, diffuse alveolar damage, organizing pneumonia, and pulmonary edema, among others.2PubMed Central. Chemotherapy-induced pulmonary complications in cancer: Significance of clinicoradiological correlation The common thread is that the cough is usually dry and nonproductive, meaning you are not coughing up much mucus. It tends to come on gradually over days to weeks rather than appearing overnight.
Drugs That Carry the Highest Lung Risk
Not all chemotherapy regimens carry equal risk. Bleomycin is one of the most well-known offenders. Pulmonary toxicity is actually the major limitation of bleomycin therapy, and it can be life-threatening in up to about one in ten patients who receive the drug.3Journal of Cancer Research. Bleomycin-Induced Lung Injury The damage involves oxidative injury to lung cells, partly because the lungs have low levels of the enzyme that normally breaks bleomycin down. In clinical reports of bleomycin-induced pneumonitis, shortness of breath and dry cough were the presenting symptoms in nearly all symptomatic patients.4PubMed. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids
Immune checkpoint inhibitors, which are increasingly used alongside or instead of traditional chemotherapy, deserve special attention. These drugs work by releasing the brakes on the immune system so it can attack cancer cells, but sometimes the immune system overreacts and attacks healthy tissue, including the lungs. This is called immune-related pneumonitis, and cough is one of its hallmark symptoms alongside shortness of breath and sometimes fever.5PubMed Central. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer One case report described a patient on an anti-PD-1 drug who developed a new nonproductive cough over the course of a week, with CT imaging showing ground-glass opacities in both lower lungs. The cough improved after steroid treatment, pointing to an immune-driven cause rather than infection.6PubMed Central. Clinical Management of Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy
Gemcitabine, methotrexate, and several targeted therapies also carry lung toxicity risk, though less dramatically than bleomycin. If you are starting a new regimen and are unsure whether your drugs have pulmonary side effects, your oncologist should be able to tell you. The risk varies not just by drug but also by dose, whether you have had prior lung radiation, and individual susceptibility.
When the Cough Is Really an Infection
Chemotherapy suppresses the immune system, and a weakened immune system opens the door to lung infections that healthy people would normally fight off easily. This is actually the most common reason for pulmonary complications during chemotherapy, more common even than direct drug toxicity.2PubMed Central. Chemotherapy-induced pulmonary complications in cancer: Significance of clinicoradiological correlation The infectious agents range widely: bacteria, common respiratory viruses, and fungi that most people would never get sick from under normal circumstances.7PubMed. Lung infections after cancer chemotherapy
An infection-related cough during chemotherapy often looks different from drug-induced lung damage. You are more likely to have a fever, to cough up discolored mucus, or to feel acutely ill rather than experiencing a slow buildup of symptoms. But these distinctions are far from reliable, and the overlap is significant enough that doctors frequently cannot tell the two apart from symptoms alone. This is one reason imaging and sometimes lab work are needed to sort out the cause.
The practical takeaway is that a cough during chemotherapy should never be casually attributed to “just a cold.” Even a mild respiratory infection can escalate quickly when your white blood cell count is low. If you develop a cough with a fever above 100.4°F (38°C), this generally warrants a same-day call to your oncology team, because febrile neutropenia is a medical emergency.
Other Reasons You Might Cough During Treatment
Drug toxicity and infection are the big two, but they are not the only causes. Chemotherapy paired with radiation to the chest substantially increases lung irritation. In a study of patients receiving both chemotherapy and radiation for lung cancer, roughly 8% developed severe radiation pneumonitis, an inflammation of the lungs that causes cough, shortness of breath, and sometimes permanent scarring.8PubMed. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer The combined effect of both therapies tends to be worse than either alone.
Gastroesophageal reflux is another underappreciated culprit. Chemotherapy-induced nausea and vomiting can worsen acid reflux, and reflux is a well-known trigger for chronic cough. Patients undergoing treatment for esophageal cancer, for example, reported reflux-associated chronic cough as a core symptom during chemotherapy and radiation.9Gastrointestinal Tumors. A qualitative study on the symptom experience and self-management strategies of patients undergoing chemotherapy and radiotherapy for esophageal cancer This type of cough can sometimes be managed by treating the reflux itself, for instance with proton pump inhibitors, rather than treating the lungs.
The tumor itself can also cause cough, especially if it involves the airways or presses on structures in the chest. Distinguishing tumor-related cough from treatment-related cough is part of the diagnostic puzzle your medical team has to sort through.
What Your Doctor Will Do to Figure Out the Cause
When you report a new or worsening cough during chemotherapy, the workup usually starts with a physical exam and a chest X-ray or CT scan. CT tends to be more informative because it can show subtle patterns, like ground-glass opacities or consolidation, that help narrow down whether the cause is drug toxicity, infection, fluid, or something else. In some cases, a procedure called bronchoalveolar lavage is performed, where fluid is introduced into a section of lung and then collected for analysis. The cell types found in that fluid can offer clues: a predominance of certain white blood cells points toward drug toxicity, while finding bacteria or fungi points toward infection.
Lung function testing, specifically a measurement of how well gases transfer across the lung lining, can also help. In patients with drug-induced lung injury, this value tends to drop. After high-dose chemotherapy and bone marrow transplant, for example, researchers found that patients who developed pulmonary symptoms showed significantly earlier and steeper declines in this measure. The decline bottomed out around 15 to 18 weeks after treatment before gradually improving, especially in patients treated with steroids.10PubMed Central. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer
Treating the Underlying Cause
If the cough stems from drug-induced pneumonitis, the first step is usually stopping or switching the offending chemotherapy agent. Corticosteroids are the cornerstone of treatment. Early detection and treatment with steroids can lead to complete resolution of pneumonitis, and the chemotherapy regimen can often be adjusted to avoid the problematic drug while continuing cancer treatment.11PubMed. Early detection and successful treatment of drug-induced pneumonitis with corticosteroids
For immune checkpoint inhibitor pneumonitis, the approach is similar. A clinical study of steroid therapy for immune-related pneumonitis treated patients with moderate-to-severe inflammation using oral corticosteroids over a six-week course. Patients with the most severe grades could also receive an initial course of intravenous steroids before switching to oral.12PubMed Central. Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study The key is catching the problem early enough that steroid treatment can prevent lasting lung scarring.
If infection is the cause, treatment depends on the organism. Bacterial infections call for antibiotics, often started empirically while culture results are pending. Fungal infections, which are more common in severely immunosuppressed patients, require antifungal drugs. Viral infections may need antivirals or supportive care. Getting the right diagnosis matters because giving steroids for what turns out to be an infection can make things worse by further suppressing the immune response.
Managing the Cough Itself
While the underlying cause is being addressed, the cough itself can be miserable and worth treating on its own. Several antitussive medications have been specifically studied in people with cancer. A review of antitussive drugs found that benzonatate, dihydrocodeine, hydrocodone, and levodropropizine were among those shown to be effective and safe at recommended doses for cancer-related cough.13PubMed. Important drugs for cough in advanced cancer
A Cochrane review looking at interventions for cough in cancer found some benefit from morphine, codeine, dihydrocodeine, levodropropizine, and sodium cromoglycate, but all the studies carried significant risk of bias, and some reported side effects. The reviewers could not draw firm practice recommendations from the available evidence.14Cochrane Database of Systematic Reviews. Interventions for cough in cancer In practice, many oncologists start with mild options like benzonatate and escalate to opioid-based cough suppressants only when the cough is severely disruptive.
Beyond medications, there are non-drug strategies worth trying. Cough suppression therapy, typically delivered by a speech pathologist, teaches techniques like pursed-lip breathing, controlled swallowing, and sipping water to interrupt the cough reflex. In clinical trials of patients with chronic refractory cough (not specifically cancer patients, but the principles translate), about 88% of those in the speech pathology group improved their cough, compared with 14% in the control group.15Chest. Evidence-Based Medicine Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer: CHEST Guideline and Expert Panel Report These interventions also include education about cough triggers, vocal hygiene, proper hydration, and breathing exercises.16PubMed. Nonpharmacological Approaches to Chronic Cough
Simple comfort measures can help as well: using a humidifier, staying well hydrated, elevating your head while sleeping if reflux is a contributor, and avoiding known irritants like strong fumes or very dry air. These are not going to resolve drug-induced pneumonitis, but they can take the edge off while medical treatment works.
When a Cough During Chemo Needs Urgent Attention
Not every cough during chemotherapy is an emergency, but some warning signs warrant immediate contact with your oncology team:
- Fever: Any temperature at or above 100.4°F (38°C) during chemotherapy is a potential sign of neutropenic infection and needs same-day evaluation.
- Worsening breathlessness: If you are getting more short of breath over hours or days, especially with activity that was previously easy, this could signal worsening pneumonitis or a serious infection.
- Coughing up blood: Even small amounts of blood in your sputum should be reported promptly.
- Chest pain or tightness: This can indicate fluid around the lungs, a blood clot, or significant inflammation.
- Rapid onset: A cough that appears suddenly and is accompanied by difficulty breathing could be a hypersensitivity reaction, which can happen within hours of a drug infusion.
Chemotherapy-related side effects can mimic common illnesses, which makes it easy for both patients and providers to initially underestimate what is happening. Err on the side of calling early. Your team would rather hear about a cough that turns out to be minor than miss one that is serious.
Why Reporting Your Symptoms Matters More Than You Think
There is a well-documented gap between what patients experience and what ends up in their medical records. A study comparing patient-reported symptoms with clinician documentation found poor agreement across eleven physical symptoms, including cough. Clinicians consistently under-reported symptoms compared to what patients themselves reported.17PubMed Central. Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation Similarly, in a study of patients undergoing chemoradiation for lung cancer, cough was one of four symptoms where patient and clinician reports significantly diverged.18Journal of Oncology Research and Therapy. The Discordance between Patient- and Clinician Reported Outcomes during (Chemo-) Radiation Therapy for Lung Cancer
In a broader assessment of symptom reporting in multicenter cancer clinical trials, clinicians reported lower levels of nearly all symptomatic side effects compared to patient self-reports over time. Agreement between the two was generally only “fair” for most symptoms.19JAMA Oncology. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials The implication is clear: if you do not specifically tell your team about your cough and how it is affecting you, there is a real chance it will not be adequately documented or addressed.
Being specific helps. Instead of saying “I have a cough,” try describing when it started, whether it is dry or productive, what makes it worse, whether it disrupts your sleep, and how it compares to last week. These details help your team distinguish between a minor nuisance and a sign of something that needs investigation.
How a Persistent Cough Affects Daily Life During Treatment
A cough might seem like a minor complaint in the context of cancer treatment, but its impact on quality of life is real and measurable. In a study of lung cancer patients undergoing chemotherapy, coughing ranked among the most common physical symptoms alongside lack of energy, pain, poor appetite, and nausea. The researchers found a clear negative relationship between symptom distress and overall quality of life.20Elsevier / PubMed Central. Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy
A persistent cough disrupts sleep, makes eating harder, strains abdominal and chest muscles that may already be sore, and creates social discomfort. For patients already dealing with fatigue and nausea, adding a relentless cough on top can feel overwhelming. This is exactly why it is worth actively managing rather than just pushing through. Treating the cough is not about comfort alone; reducing symptom burden frees up physical and emotional energy that you need for the rest of treatment and recovery.